Sanofi Looks To Build On Dupixent Dominance With OX40L Drug

Amlitelimab Could Be Dosed Less Frequently

Sanofi is looking to build its position in immunology, with a new anti-inflammatory candidate, amlitelimab, which could potentially help patients who do not respond to its blockbuster Dupixent.

Sanofi has unveiled positive Phase II data from amlitelimab in atopic dermatitis, backing up its belief that it could be a first and best-in-class novel therapy targeting the OX40 ligand.

The candidate was the key asset acquired through Sanofi’s $1.1bn buyout of biotech Kymab Ltd. two years ago, and...